

Hector Tamez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10565900/publications.pdf>

Version: 2024-02-01

47
papers

5,244
citations

257450

24
h-index

265206

42
g-index

47
all docs

47
docs citations

47
times ranked

6473
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. <i>Circulation</i> , 2022, 145, 97-106.	1.6	20
2	Predicting Residual Angina After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the OPEN-CTO Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024056.	3.7	5
3	Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006589.	2.2	20
4	Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. <i>EuroIntervention</i> , 2021, 17, e380-e387.	3.2	32
5	The Impact of Peripheral Artery Disease in Chronic Total Occlusion Percutaneous Coronary Intervention (Insights From PROGRESS-CTO Registry). <i>Angiology</i> , 2020, 71, 274-280.	1.8	6
6	Impact of adherence to the hybrid algorithm for initial crossing strategy selection in chronic total occlusion percutaneous coronary intervention. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 74, 1023-1031.	0.6	1
7	Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 306-308.	1.6	8
8	Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement. <i>Circulation</i> , 2020, 142, 203-213.	1.6	23
9	Retrograde Chronic Total Occlusion Percutaneous Coronary Intervention via Saphenous Vein Graft. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 517-526.	2.9	21
10	Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. <i>American Heart Journal</i> , 2019, 212, 64-71.	2.7	23
11	Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 651-658.	2.9	19
12	Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008231.	3.9	17
13	Contemporary Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention in the United States. <i>JAMA Cardiology</i> , 2019, 4, 100.	6.1	45
14	Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2019, 4, 110.	6.1	26
15	Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI. <i>JAMA Cardiology</i> , 2017, 2, 673.	6.1	6
16	Type 4a myocardial infarction: Incidence, risk factors, and long-term outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 849-856.	1.7	23
17	Procedure Logging in Interventional Cardiology Training Curriculum. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2798-2801.	2.8	1
18	Serum phospholipid fraction of polyunsaturated fatty acids is the preferred indicator for nutrition and health status in hemodialysis patients. <i>Journal of Nutritional Biochemistry</i> , 2016, 38, 18-24.	4.2	2

#	ARTICLE	IF	CITATIONS
19	African Americans with left ventricular hypertrophy and chronic kidney disease: what should we do?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1969-1970.	0.7	0
20	Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 903-913.	6.1	213
21	Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. <i>International Journal of Nephrology</i> , 2015, 2015, 1-9.	1.3	66
22	Nutritional Vitamin D Supplementation in Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 611-619.	4.5	69
23	Vitamin D and Its Effects on the Heart. , 2015, , 107-116.		0
24	Vitamin D and chronic kidney diseaseâ€“mineral bone disease (CKDâ€“MBD). <i>BoneKey Reports</i> , 2014, 3, 498.	2.7	55
25	Vitamin Dâ€“Binding Protein and Vitamin D Status of Black Americans and White Americans. <i>New England Journal of Medicine</i> , 2013, 369, 1991-2000.	27.0	898
26	Reply to â€œThe role of fibroblast growth factor-23 in left atrial volumeâ€•. <i>American Heart Journal</i> , 2013, 165, e23.	2.7	1
27	Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. <i>Kidney International</i> , 2013, 83, 1130-1135.	5.2	45
28	Impact of new vitamin D data on future studies and treatment. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 377-382.	2.0	7
29	Does vitamin D modulate blood pressure?. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 204-209.	2.0	53
30	Carbamylation of Serum Albumin and Erythropoietin Resistance in End Stage Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1927-1934.	4.5	37
31	Active Vitamin D Treatment for Reduction of Residual Proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1863-1871.	6.1	126
32	Fatty Acids and Other Risk Factors for Sudden Cardiac Death in Patients Starting Hemodialysis. <i>American Journal of Nephrology</i> , 2013, 38, 12-18.	3.1	24
33	Phospholipid PUFA: a better indicator for assessing health risks. <i>FASEB Journal</i> , 2013, 27, 1072.16.	0.5	0
34	Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 674.	7.4	495
35	Vitamin D and hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 492-499.	2.0	37
36	Low Blood Levels of Long-Chain nâ€“3 Polyunsaturated Fatty Acids in US Hemodialysis Patients: Clinical Implications. <i>American Journal of Nephrology</i> , 2012, 36, 451-458.	3.1	34

#	ARTICLE	IF	CITATIONS
37	Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. <i>American Heart Journal</i> , 2012, 164, 902-909.e2.	2.7	112
38	Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease. <i>PLoS ONE</i> , 2010, 5, e9246.	2.5	43
39	Role of Vitamin D and Vitamin D Analogs for Bone Health and Survival in Chronic Kidney Disease. , 2010, , 955-965.		0
40	Low Plasma Level of Cathelicidin Antimicrobial Peptide (hCAP18) Predicts Increased Infectious Disease Mortality in Patients Undergoing Hemodialysis. <i>Clinical Infectious Diseases</i> , 2009, 48, 418-424.	5.8	131
41	Plasma Gelsolin and Circulating Actin Correlate with Hemodialysis Mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1140-1148.	6.1	98
42	Phosphorus Binders and Survival on Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 388-396.	6.1	341
43	Reply to DiNubile. <i>Clinical Infectious Diseases</i> , 2009, 49, 164-165.	5.8	0
44	Klotho Variants and Chronic Hemodialysis Mortality. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1847-1855.	2.8	54
45	Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis. <i>New England Journal of Medicine</i> , 2008, 359, 584-592.	27.0	1,546
46	Impact of Activated Vitamin D and Race on Survival among Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1379-1388.	6.1	156
47	Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 16810-16815.	7.1	305